180.95
+1.18(+0.66%)
Currency In USD
| Previous Close | 179.77 |
| Open | 180.47 |
| Day High | 181.33 |
| Day Low | 176.48 |
| 52-Week High | 200 |
| 52-Week Low | 49 |
| Volume | 99,349 |
| Average Volume | 254,893 |
| Market Cap | 6.31B |
| PE | -94.24 |
| EPS | -1.92 |
| Moving Average 50 Days | 161.2 |
| Moving Average 200 Days | 96.98 |
| Change | 1.18 |
If you invested $1000 in Belite Bio, Inc (BLTE) since IPO date, it would be worth $17,086.87 as of February 21, 2026 at a share price of $180.95. Whereas If you bought $1000 worth of Belite Bio, Inc (BLTE) shares 3 years ago, it would be worth $5,438.83 as of February 21, 2026 at a share price of $180.95.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Belite Bio Announces Participation at the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO)
GlobeNewswire Inc.
Jan 29, 2026 1:00 PM GMT
SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have signifi
Belite Bio Completes Enrollment in the DRAGON II Clinical Trial of Tinlarebant for Stargardt Disease (STGD1)
GlobeNewswire Inc.
Jan 27, 2026 1:00 PM GMT
Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease, having met the primary endpoint in the pivotal, global Phase 3 DRAGON trial with 36% reduction in lesion growth (p-value=0.0033)60 adolescent STGD1
Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares
GlobeNewswire Inc.
Dec 02, 2025 3:37 AM GMT
SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have signifi